Results 11 to 20 of about 49,826 (161)
Safety of Sodium-Glucose Co-Transporter 2 Inhibitors [PDF]
The American Journal of Cardiology, 2019 Sodium-glucose co-transporter 2 (SGLT2) inhibitors have a well-defined safety profile based on data obtained from numerous clinical trials, including cardiovascular outcomes trials (CVOTs) and postmarketing pharmacovigilance reporting. Adverse events including risk of genital mycotic infection and volume depletion-related events are consistent with the
Janet B. McGill, Savitha Subramanian
openaire +3 more sources
Sodium-glucose co-transporter-2 inhibitors and epicardial adiposity
European Journal of Pharmaceutical Sciences, 2023 Epicardial adipose tissue is a layer of adipocytes that physiologically surround the myocardium and play some physiologic roles in normal heart function. However, in pathologic conditions, the epicardial adipose tissue can present a potent cardiac risk factor that is capable of impairing heart function through several pathways, increasing the risk of ...
Habib Yaribeygi +4 more
openaire +2 more sources
Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea [PDF]
Endocrinology and Metabolism, 2020 Background We assessed the glucose-lowering efficacy of adding empagliflozin versus dose escalating existing medications in patients with uncontrolled type 2 diabetes (T2D).
Yujin Shin +4 more
doaj +1 more source
Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor [PDF]
Korean Journal of Medicine, 2014 Correspondence to Jeong Hyun Park, M.D., Ph.D. Paik Institute for Clinical Research, Department of Internal Medicine, Pusan Paik Hospital, Inje University College of Medicine, 75 Bokji-ro, Busanjin-gu, Busan 614-735, Korea Tel: +82-51-890-6074, Fax: +82-51-892-0273, E-mail: pjhdoc@chol.com Copyrightc 2014 The Korean Association of Internal Medicine ...
Mi-kyung Kim, Jeong Hyun Park
openaire +1 more source
Клинический разбор в общей медицине, 2021 The diabetic ketoacidosis (DKA) is the most frequent urgent condition in patients with diabetes mellitus which requires hospitalization and results to mortality. The most common causes of DKA are the presence of concomitant diseases in diabetic patients,
Diana Sh. Avzaletdinova +3 more
doaj +1 more source
Genito-urinary infection risk estimates during sodium glucose co-transporter 2 inhibitor exposure in everyday clinical practice. [PDF]
Farmacja Polska, 2021 Genito-urinary infection risk estimates during sodium glucose co-transporter 2 inhibitor exposure in everyday clinical practice. Type 2 diabetes mellitus, cardiovascular diseases and congestive heart failure are known to be a cause of growing ...
Beata Jacuś +3 more
doaj +1 more source
SGLT2 Inhibitors for Nephrologists
European Medical Journal Nephrology, 2022 Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are the mainstay of therapy for the prevention of progressive renal damage in diabetic and non-diabetic kidney diseases, especially glomerulonephritides.
Mufti Baleegh-ur-Raheem Mahmood +1 more
doaj +1 more source
Harms and benefits fo sodium-glucose co-transporter 2 inhibitors [PDF]
Australian Prescriber, 2020 Sodium-glucose co-transporter 2 inhibitors are oral glucose-lowering drugs that increase the urinary excretion of glucose. In patients with type 2 diabetes and cardiovascular disease they reduce all-cause mortality, cardiac mortality, rates of hospitalisation for heart failure and the progression of renal disease There are adverse effects related to ...
Chesterman, Thomas, Thynne, Tilenka RJ
openaire +2 more sources
Pharmaceutics, 2023 Type 2 diabetes mellitus is a major health problem worldwide with a steadily increasing prevalence reaching epidemic proportions. The major concern is the increased morbidity and mortality due to diabetic complications.
Melpomeni Peppa +7 more
doaj +1 more source
Cardiovascular Diabetology, 2023 Sodium-glucose co-transporter-2 inhibitors are used in the treatment of diabetes but are also emerging as cardioprotective agents in heart diseases even in the absence of type 2 diabetes.
Julia Hoehlschen +3 more
doaj +1 more source